TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30650997

Group type: EXPERIMENTAL
Intervention: Model 1 (decision tree)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Model 2 (random forest)
Number of subjects: 55
Study: 30074294

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 502

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 502
Study: 26946619

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied with direct current (DC) on acupoints Pucan (BL 61) and Shenmai (BL 62) for 20 min.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group received no TENS electrode treatments.
Number of subjects: 82
Study: 24448103

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 22266414

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20586527

Group type: EXPERIMENTAL
Intervention: Left-hemispheric deep brain stimulation (DBS)
Number of subjects: 12
Study: 17846391

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (ergocalciferol or cholecalciferol) with daily doses varying from 300 to 2000 IU, mean daily dose of 528 IU.
Number of subjects: 57311

Group type: EXPERIMENTAL
Intervention: Calcium supplements (added in some trials).
Number of subjects: 57311

Group type: COMPARATOR
Intervention: Control group (placebo or no vitamin D supplementation).
Number of subjects: 57311
Study: 16355950

Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride
Number of subjects: 75

Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 75
Study: 11942445

Group type: EXPERIMENTAL
Intervention: Educational outreach visits to practices that received two of four guidelines.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Educational outreach visits to smaller practices (two or fewer full-time equivalent practitioners).
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Educational outreach visits to larger practices.
Number of subjects: 70
Study: 9476875

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (500 microg via small-volume metal spacer)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 22
Study: 7637478

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin once daily (n = 176)
Number of subjects: 339

Group type: COMPARATOR
Intervention: No prophylaxis (Control group, n = 163)
Number of subjects: 339
Study: 2795725

Group type: EXPERIMENTAL
Intervention: Doxepin 50 mg at bedtime for the first 2 weeks, increased by 25 mg in the morning for the last week of a 3-week treatment period.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Doxepin treatment
Number of subjects: 19
Study: 319356

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg four times daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30628860

Group type: EXPERIMENTAL
Intervention: Telehealth device for in-home use
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 24
Study: 27821374

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PTX-B)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 223
Study: 25988935

Group type: EXPERIMENTAL
Intervention: r‐ATG/EVR (n = 85)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: BAS/EVR (n = 102)
Number of subjects: 288

Group type: COMPARATOR
Intervention: BAS/MPS (n = 101)
Number of subjects: 288
Study: 23234725

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (DF) treatment for chronic hepatitis B infection for at least 5 years
Number of subjects: 641
Study: 21623240

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 395

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 395
Study: 19460254

Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (4-FDC) regimen
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Single tablet regimen (ST)
Number of subjects: 1159
Study: 16678649

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS XR) 10, 20, and 30 mg/d
Number of subjects: 57

Group type: COMPARATOR
Intervention: Atomoxetine 0.5 and 1.2 mg/kg per day
Number of subjects: 57
Study: 14666741

Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control plus Whitening (CTCW)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste (CT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Crest Regular (CR)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Crest Tartar Control (CTC)
Number of subjects: 4
Study: 10809298

Group type: EXPERIMENTAL
Intervention: Functional noise cancellation devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfunctional noise cancellation devices
Number of subjects: 0
Study: 8617188

Group type: EXPERIMENTAL
Intervention: Green tea (300 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Black tea (300 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Green tea with milk (300 ml tea + 100 ml milk)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Black tea with milk (300 ml tea + 100 ml milk)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no tea)
Number of subjects: 10
Study: 1591150

Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional long stay hospital wards
Number of subjects: 0
Study: 3001562

Group type: EXPERIMENTAL
Intervention: Alsactide (10 or 100 micrograms i.v. as bolus followed by the same dose infused over 2 hours)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alsactide (100 micrograms i.v. as bolus plus 100 micrograms infused over 2 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30909923

Group type: EXPERIMENTAL
Intervention: Add-on phototherapy (one winter under spaced sessions of phototherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for vitamin D supplementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (TAT)
Number of subjects: 0
Study: 30711299

Group type: EXPERIMENTAL
Intervention: Conversations about the future self
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conversations about the present self, another child's present self, or another child's future self
Number of subjects: 68
Study: 28555205

Group type: EXPERIMENTAL
Intervention: Conventional drills
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 25939333

Group type: EXPERIMENTAL
Intervention: Polymorphic Form A of ponesimod in a capsule, 20 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Polymorphic Form C of ponesimod in a capsule, 20 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Polymorphic Form C of ponesimod in a tablet, 40 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Polymorphic Form C of ponesimod in a capsule, 40 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All formulations of ponesimod
Number of subjects: 26
Study: 24251085

Group type: EXPERIMENTAL
Intervention: Exercise class
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 21676993

Group type: EXPERIMENTAL
Intervention: Medical care management intervention
Number of subjects: 407

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 407
Study: 19505495

Group type: EXPERIMENTAL
Intervention: Minimal number of stimulus presentations per session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varying number of trials per session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study: 17014629

Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.25%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cyclosporine 1%
Number of subjects: 20
Study: 15228062

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (no vitamin supplementation)
Number of subjects: 40
Study: 11572891

Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide (pCyc)
Number of subjects: 202
Study: 9227007

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate suppository (2.5 mg/kg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chloroquine sulphate syrup (2.5 mg/kg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chloroquine (2.5 mg/kg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate suppository and chloroquine sulphate syrup
Number of subjects: 69
Study: 7965295

Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 25
Study: 3296793

Group type: EXPERIMENTAL
Intervention: D-phenylalanine (20 mg/kg per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29402862

Group type: EXPERIMENTAL
Intervention: Rehearsal training (23 participants), rehearsing the PM cue words during intention retention.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Imagery training (21 participants), vividly imagining a mental picture to memorize the connection between the PM cue words and related actions during intention formation.
Number of subjects: 44
Study: 27391972

Group type: EXPERIMENTAL
Intervention: Children with inflammation (CRP > 5 mg/L) and/or malaria parasitaemia
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Infection defined as clinical malaria or parasitaemia with/without fever
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Infection defined using CRP only
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Infection definitions that included parasitaemia (Model 5)
Number of subjects: 1943
Study: 24948336

Group type: EXPERIMENTAL
Intervention: Whole-grain foods
Number of subjects: 83

Group type: COMPARATOR
Intervention: Refined-grain foods
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study: 23341971

Group type: EXPERIMENTAL
Intervention: Serum vitamin D (25‐OHD) levels
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Charlson score
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Severe COPD
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Very severe COPD
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Smoking history of more than 40 pack years
Number of subjects: 462
Study: 22002277

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia
Number of subjects: 32
Study: 18026891

Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.08 mg/kg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study: 15845611

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 272
Study: 12568409

Group type: EXPERIMENTAL
Intervention: HRT (n = 151) - 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Number of subjects: 331

Group type: COMPARATOR
Intervention: Non-HRT (n = 180) - 93 mg calcium alone or in combination with vitamin D3 (100-300 IU)/day
Number of subjects: 331
Study: 10860412

Group type: EXPERIMENTAL
Intervention: Regression-based methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various techniques for detecting LRP onset
Number of subjects: 0
Study: 9327716

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg daily)
Number of subjects: 24
Study: 8093403

Group type: EXPERIMENTAL
Intervention: Bone density of the femoral neck
Number of subjects: 8134

Group type: EXPERIMENTAL
Intervention: Lowest quartile of femoral neck bone density
Number of subjects: 8134

Group type: COMPARATOR
Intervention: Bone density measurements at various sites (femoral neck, spine, radius, calcaneus)
Number of subjects: 8134
Study: 3306385

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 28422544

Group type: EXPERIMENTAL
Intervention: Balance and coordination exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 0
Study: 27133791

Group type: EXPERIMENTAL
Intervention: Short-term healing group (8 to 10 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Long-term healing group (18 to 20 weeks)
Number of subjects: 44
Study: 24397981

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg per day (n=82)
Number of subjects: 165
Study: 22851487

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus premeal glulisine
Number of subjects: 388

Group type: COMPARATOR
Intervention: Twice‐daily premix 75/25 or 70/30 analog insulin
Number of subjects: 388
Study: 15912493

Group type: EXPERIMENTAL
Intervention: Shark cartilage product
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 12701946

Group type: EXPERIMENTAL
Intervention: Paper Standard Gamble (PSG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard Gamble (SG)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Test-retest PSG
Number of subjects: 64
Study: 9803069

Group type: COMPARATOR
Intervention: 25 micrograms of intravaginal misoprostol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 micrograms of intravaginal misoprostol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25 micrograms and 50 micrograms of intravaginal misoprostol
Number of subjects: 50
Study: 7637222

Group type: EXPERIMENTAL
Intervention: Absorbable staples (GIA 75‐.060; United States Surgical Co., Ltd.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Un-absorbable staples (Multifire GIS 60 Titanium (3.8mm); United States Surgical Co., Ltd.)
Number of subjects: 20
Study: 2676800

Group type: EXPERIMENTAL
Intervention: Piroxicam gel (4 x 5 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diclofenac gel (4 x 40 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 69
Study: 350328

Group type: EXPERIMENTAL
Intervention: L-tryptophan with pyridoxine and ascorbic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31787454

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 100 μg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Epidural fentanyl 100 μg
Number of subjects: 98
Study: 28985106

Group type: EXPERIMENTAL
Intervention: Connecticut intrusion arch (CIA) for a mean period of 5.8 ± 1.27 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional leveling and alignment using continuous archwire mechanics for 6.1 ± 0.81 months
Number of subjects: 28
Study: 27548306

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 83
Study: 24064007

Group type: EXPERIMENTAL
Intervention: Waist belt on
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waist belt off
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased waist circumference (WC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal waist circumference (WC)
Number of subjects: 24
Study: 21518152

Group type: EXPERIMENTAL
Intervention: Lay health trainers (LHT) intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (health promotion literature only)
Number of subjects: 110
Study: 20720560

Group type: EXPERIMENTAL
Intervention: CoQ(10) 300 mg daily (n=93)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo (n=93)
Number of subjects: 186
Study: 18467322

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Bivalirudin and UFH)
Number of subjects: 100
Study: 16085660

Group type: EXPERIMENTAL
Intervention: 0.25 mg/day ganirelix (standard dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2 mg/day ganirelix (high dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0.6 mg/day buserelin (long protocol)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Natural cycle
Number of subjects: 31
Study: 11823391

Group type: EXPERIMENTAL
Intervention: AV‐impulse(TM) (rapid IPC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: SeQuel(TM) (standard IPC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional LPD with IPC devices
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: New LPD (Levitator(TM)) with IPC devices
Number of subjects: 3
Study: 10065073

Group type: COMPARATOR
Intervention: Database-generated summaries
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Dictation-generated summaries
Number of subjects: 293
Study: 7582397

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral estradiol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2261203

Group type: EXPERIMENTAL
Intervention: Radiotherapy and chemotherapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Definite RBP
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Probable RBP
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Entire plexus affection
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Upper trunk affection
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lower trunk affection
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Definite level assessment
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lymphedema presence
Number of subjects: 79
Study: 532690

Group type: EXPERIMENTAL
Intervention: Viloxazine 50 mg three times a day during the first week followed by 100 mg three times a day during the next three weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amitriptyline 25 mg three times a day during the first week followed by 50 mg three times a day during the following three weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 32
Study: 30945491

Group type: EXPERIMENTAL
Intervention: Fire needle stimulation at Sihua acupoints combined with chemotherapy (paclitaxel + cisplatin or gemcitabine + cisplatin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paclitaxel combined with cisplatin or gemcitabine plus cisplatin (chemotherapy)
Number of subjects: 60
Study: 28581209

Group type: EXPERIMENTAL
Intervention: Exenatide (continuous 72-hour intravenous infusion)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 38
Study: 26531700

Group type: EXPERIMENTAL
Intervention: Interferon-beta treatment in overweight or obese patients (BMI≥25kg/m²)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Interferon-beta treatment in normal-weight patients (BMI<25kg/m²)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Interferon-beta treatment in overweight or obese patients (BMI>25)
Number of subjects: 86
Study: 23794458

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 194
Study: 21051930

Group type: EXPERIMENTAL
Intervention: CMAB009 (anti-EGFR monoclonal antibody)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CMAB009 (100 mg/m2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CMAB009 (250 mg/m2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CMAB009 (400 mg/m2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CMAB009 (multiple infusions)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CMAB009
Number of subjects: 18
Study: 19944362

Group type: EXPERIMENTAL
Intervention: Ivabradine (IVA) administered 12 hours after PCI, twice per day.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Metoprolol (METO) administered 12 hours after PCI, twice per day.
Number of subjects: 155
Study: 17717928

Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WLC)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined group (WLC + FLX)
Number of subjects: 108
Study: 15547059

Group type: EXPERIMENTAL
Intervention: Multilevel school based intervention
Number of subjects: 2678
Study: 11505966

Group type: EXPERIMENTAL
Intervention: Colgate Total Professional toothbrush
Number of subjects: 85

Group type: COMPARATOR
Intervention: Oral-B Cross Action toothbrush
Number of subjects: 85
Study: 9505916

Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 308
Study: 7998047

Group type: EXPERIMENTAL
Intervention: lisinopril 10‐40 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: nifedipine 20‐80 mg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 97
Study: 2973596

Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 157

Group type: COMPARATOR
Intervention: cefotaxime + tobramycin
Number of subjects: 157
Study: 30275095

Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) administered to healthy male volunteers, specific dosage not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dried Blood Spot (DBS) technique for measuring BNZ levels.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography-positive electrospray tandem mass spectrometry method used for analysis.
Number of subjects: 0
Study: 27151271

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 698